Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of AR-42 and Decitabine in Acute Myeloid Leukemia

Next Previous
X
Search
Trial Profile

Phase I Study of AR-42 and Decitabine in Acute Myeloid Leukemia

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decitabine (Primary) ; REC 2282 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Biomarker; Therapeutic Use

    • Most Recent Events

    • 07 Oct 2021 Results (n=57) of Pop PK analysis assessing whether or not use of body size-normalized dosing could reduce observed pharmacokinetic variability using data from two clinical studies NCT01129193 and NCT01798901 published in the European Journal of Drug Metabolism and Pharmacokinetics
    • 21 Mar 2020 Results (n=55) of NCT01129193 (the FIH) and NCT01798901 assessing pharmacokinetic analysis for evaluation of oral absorption models and body size descriptors as potential sources of inter-individual variability in REC- 2282 PK, presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 12 Mar 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top